Boston Scientific (BSX) Cash & Current Investments (2009 - 2026)

Boston Scientific has disclosed Cash & Current Investments across 18 years of filings, most recently posting $1.5 billion for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $1.5 billion, up 100.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 100.41% YoY), and the FY2025 annual result was $2.0 billion, up 224.26% from the prior year.
• Cash & Current Investments came in at $1.5 billion for Q1 2026 at Boston Scientific, down from $2.0 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.9 billion in Q2 2024 to a low of $276.0 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $865.0 million (2023), against an average of $1.1 billion.
• Across the five-year window, Cash & Current Investments tumbled 89.68% in 2022 and jumped 583.8% in 2024, its largest moves.
• Boston Scientific's Cash & Current Investments stood at $928.0 million in 2022, then decreased by 6.79% to $865.0 million in 2023, then decreased by 29.94% to $606.0 million in 2024, then surged by 224.26% to $2.0 billion in 2025, then retreated by 26.06% to $1.5 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.5 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.